Skip to main content
. 2018 May 11;9(36):24548–24560. doi: 10.18632/oncotarget.24647

Figure 3. The efficacy evaluation of apatinib in the phase II clinical trial in patients with non-triple-negative metastatic breast cancer.

Figure 3

(A) Kaplan-Meier estimates of progression free survival (PFS). (B) Kaplan-Meier estimates of overall survival (OS). (Cited from: Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014; 14: 820. doi: 10.1186/1471-2407-14-820.)